anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cytokine storm (CS) is linked with macrophage dysfunction and acute lung injury (ALI), which can lead to patient mortality. Glycolysis is preferentially exploited by the pro-inflammatory macrophages, in which pyruvate kinase M2 (PKM2) is a critical enzyme. The mechanism underlying the link between CS and ALI involves cell death, with the recently discovered programmed cell death known as ferroptosis being involved. However, the relationship between the glycolysis and ferroptosis in the context of CS-related ALI remains unclear. CS-associated ALI induced by poly I:C (10 mg/kg, i.v) and LPS (5 mg/kg, i.p) (IC: LPS) exhibit significant ferroptosis. Ferrostatin-1 (ferroptosis inhibitor) treatment attenuated IC:LPS‑induced mortality and lung injury. Moreover, Alveolar macrophage (AM) from IC:LPS model exhibited enhanced glycolysis and PKM2 translocation. The administration of ML-265(PKM2 monomer/dimer inhibitor) resulted in the formation of a highly active tetrameric PKM2, leading to improved survival and attenuation of ALI. Furthermore, ML-265 treatment decreased ferroptosis and restored the balance between anaerobic glycolysis and oxidative phosphorylation. Notably, in patients with lung infection, intracellular expression level of PKM2 were correlated with circulating inflammation. Enhanced ferroptosis and PKM2 nuclear translocation was noticed in CD14+ blood monocytes of lung infection patients with CS. In conclusion, PKM2 is a key regulatory node integrating metabolic reprograming with intra-nuclear function for the regulation of ferroptosis. Targeting PKM2 could be explored as a potential means in the future to prevent or alleviate hyper-inflammatory state or cytokines storm syndrome with aberrant ferroptotic cell death.
Lung adenocarcinoma (LUAD) is the most frequent histological subtype of lung cancer, which is the most common malignant tumor and the main cause of cancer-related mortality globally. Recent reports revealed that long non-coding RNA (lncRNA) of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) plays a crucial role in tumorigenesis and metastasis development in lung cancer. However, the contribution of MALAT1 genetic variants to the development of LUAD is unclear, especially in epidermal growth factor receptor (EGFR) mutation status. In this study, 272 LADC patients with different EGFR status were recruited to dissect the allelic discrimination of the MALAT1 polymorphisms at rs3200401, rs619586, and rs1194338. The findings of the study showed that MALAT1 polymorphisms rs3200401, rs619586, and rs1194338 were not associated to LUAD susceptibility; however, rs3200401 polymorphisms was significantly correlated to EGFR wild-type status and tumor stages in LUAD patients in dominant model (p=0.016). Further analyses using the datasets from The Cancer Genome Atlas (TCGA) revealed that lower MALAT1 mRNA levels were associated with the advanced stage, and lymph node metastasis in LADC patients. In conclusion, our results showed that MALAT1 rs3200401 polymorphisms dramatically raised the probability of LUAD development.
Objective: Approximately 30% of adults globally suffer from sleep disorders. However, there are few longitudinal studies on the association between dietary vitamin C and sleep disorders. This study aimed to investigate the association between dietary vitamin C intake and various types of sleep disorders, including sleep apnea and insomnia. Methods: We enrolled 68,221 participants from the UK Biobank. Dietary vitamin C intake was assessed using a 24 h dietary recall questionnaire. We employed a Cox regression model to assess the association between dietary vitamin C and sleep disorders and used restricted cubic spline models to investigate potential nonlinear relationships. Stratified and sensitivity analyses were also conducted to validate the findings. Results: The results indicated that vitamin C intake at the Q4 level (132.88-191.51 mg/d) was significantly associated with a reduced risk of sleep disorders, with an HR (95% CI) of 0.78 (0.65-0.94), and against sleep apnea, with an HR (95% CI) of 0.75 (0.62-0.92). The protective effect persisted significant in stratified analyses of men and those aged ≤ 60 years; the results were consistent in the sensitivity analyses. Conclusions: Our findings suggest that sufficient dietary vitamin C intake may help to prevent sleep disorders.
The invention discloses an inflammation-diminishing and cough-relieving pharmaceutical composition and a preparation method thereof. The inflammation-diminishing and cough-relieving pharmaceutical composition is prepared from elaeagnus pungens leaf, platycodon root, princens, sessile stemona root, negundo chastetree fruit, Chinese ephedra, poppy capsule, upright ladybell root and common andrographis herb. The inflammation-diminishing and cough-relieving pharmaceutical composition has the functions of diminishing inflammation, relieving cough, reducing phlegm and relieving asthma. The inflammation-diminishing and cough-relieving pharmaceutical composition can be utilized for treating cough, much phlegm, chest distention, reversed flow of qi and the like. The inflammation-diminishing and cough-relieving pharmaceutical composition has obvious treatment effects, and does not have toxic and side effects. The preparation method has the advantages of simple and clear production processes, easily controlled production quality and low product cost. The inflammation-diminishing and cough-relieving pharmaceutical composition can satisfy patient demands.
In Weeks 1 and 6, people in the intervention group will meet with a Registered Dietitian and an Exercise Physiologist for personalized sessions. They will receive a pedometer and instructions on how to log in to the e-health site (https://sspanli.mtroyal.ca). They will wear the pedometer daily and log in to the website each week for a nutrition education session, a weekly step goal, and tips.
The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.
The invention relates to application of Rutaevin in preparation of a medicine for treating gastric cancer, belonging to the field of biological medicine. Application of Rutaevin in preparing medicine for treating gastric cancer. It can obviously inhibit the proliferation of gastric cancer cells and obviously promote the death of gastric cancer cells. It can obviously inhibit the migration and invasion of gastric cancer cells. It can obviously destroy the form of gastric cancer cells, resulting in swelling and death of the cancer cells. The medicine for treating gastric cancer comprises an effective amount of a compound Rutaevin and a pharmaceutically acceptable carrier. The dosage form is one of powder, fine granule, capsule or tablet. The invention has the following advantages: the compound Rutaevin can obviously inhibit proliferation of gastric cancer cells, obviously destroy gastric cancer cell skeletons and promote apoptosis of gastric cancer cells; provides a new compound medicine for the treatment of gastric cancer; provides a new application direction for the compound Rutaevin.
Myoepithelial carcinoma (MECA) is a rare type of carcinoma for which the clinicopathological features and prognostic factors have not yet been fully clarified. A retrospective study of 42 patients diagnosed with salivary gland MECA was performed, focusing on the clinicopathological features and prognostic factors. Of the 42 patients, 20 died of cancer, 20 lived without tumour, one lived with distant metastasis, and one was lost to follow-up. Overall, 69.0% had tumour recurrence, 16.7% had cervical nodal metastasis, and 21.4% had distant metastasis. The 5-year overall survival rate was 70.2%. Kaplan-Meier analysis revealed that patients with pathological positive lymph nodes (pN+), multiple recurrences of tumour, and higher histological grade had worse overall survival. Multivariate Cox analysis indicated pN+ and higher histological grade to be independent predictors of decreased survival. The 5-year overall survival rate in the pN0 group was 87.5%, while that in the pN+ group was 28.6%. In conclusion, myoepithelial carcinoma can be defined as a tumour with a high incidence of recurrence and poor prognosis, especially in pN+ patients. Pathological positive lymph nodes and histological grade may serve as predictors of survival.
BACKGROUND: Stroke and thromboembolism in nonvalvular atrial fibrillation (NVAF) primarily arise from thrombi or sludge in the left atrial appendage (LAA). Comprehensive insight into the characteristics of these formations is essential for effective risk assessment and management.
METHODS: We conducted a single-center retrospective observational of 176 consecutive NVAF patients with confirmed atrial/appendage thrombus or sludge determined by a pre-ablation transesophageal echocardiogram (TEE) from December 2017 to April 2019. We obtained clinical and echocardiographic characteristics, including left atrial appendage emptying velocity (LAAeV) and filling velocity (LAAfV). Data analysis focused on identifying the morphology and location of thrombus or sludge. Patients were divided into the solid thrombus and sludge groups, and the correlation between clinical and echocardiographic variables and thrombotic status was analyzed.
RESULTS: Morphological classification: In total, thrombi were identified in 78 patients, including 71 (40.3%) mass and 7 (4.0%) lamellar, while sludge was noted in 98 (55.7%). Location classification: 92.3% (72/78) of patients had thrombus confined to the LAA; 3.8% (3/78) had both LA and LAA involvement; 2.7% (2/78) had LA, LAA and RAA extended into the RA, the remained 1.2%(1/78) was isolated to RAA. 98.0% (96/98) of patients had sludge confined to the LAA; the remaining 2.0% (2/98) were present in the atrial septal aneurysm, which protrusion of interatrial septum into the RA. The thrombus and sludge groups showed low LAAeV (19.43 ± 9.59 cm/s) or LAAfV (17.40 ± 10.09 cm/s). Only LA dimension ≥ 40 mm was independently associated with the thrombus state in the multivariable model.
CONCLUSION: This cohort study identified rare thrombus morphology and systematically summarized the classification of thrombus morphology. The distribution of thrombus and sludge outside limited to LAA was updated, including bilateral atrial and appendage involvement and rare atrial septal aneurysm sludge. LAAeV and LAAfV were of limited value in distinguishing solid thrombus from sludge.
CLINICAL TRIAL NUMBER: ChiCTR-OCH-13,003,729.
A 10-month-old female neutered domestic shorthair cat presented with a history of urinary incontinence and recurrent bacterial cystitis since 2 months of age. Physical examination was unremarkable other than vulval hypoplasia. Genitourinary dysplasia was diagnosed following a physical examination, CT imaging and retrograde positive contrast urethrocystography. Attempted medical management of the urinary incontinence was unsuccessful. Surgical treatment consisted of cystourethroplasty combined with artificial urethral sphincter placement, resulting in marked improvement of urinary continence. Following multiple adjustments of the artificial urethral sphincter near-total continence was achieved, which was maintained at 10 months post-surgery.
Subjects are randomized to receive Placebo which is inactive saline (sterile salt water solution). The Subjects are injected with a comparable amount of placebo solution (2cc-3cc) as received by those randomized to receive active study drug. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.
BACKGROUND: Genetic testing for cardiac channelopathies is the standard of care. However, many rare genetic variants remain classified as variants of uncertain significance (VUS) due to lack of epidemiological and functional data. Whether deep protein language models may aid in VUS resolution remains unknown. Here, we set out to compare how 2 deep protein language models perform at VUS resolution in the 3 most common long-QT syndrome-causative genes compared with the gold-standard patch clamp.
METHODS: A total of 72 rare nonsynonymous VUS (9 KCNQ1, 19 KCNH2, and 50 SCN5A) were engineered by site-directed mutagenesis and expressed in either HEK293 cells or TSA201 cells. Whole-cell patch-clamp technique was used to functionally characterize these variants. The protein language models, evolutionary scale modeling, version 1b and AlphaMissense, were used to predict the variant effect of missense variants and compared with patch clamp.
RESULTS: Considering variants in all 3 genes, the evolutionary scale modeling, version 1b model had a receiver operating characteristic curve-area under the curve of 0.75 (P=0.0003). It had a sensitivity of 88% and a specificity of 50%. AlphaMissense performed well compared with patch-clamp with an receiver operating characteristic curve-area under the curve of 0.85 (P<0.0001), sensitivity of 80%, and specificity of 76%.
CONCLUSIONS: Deep protein language models aid in VUS resolution with high sensitivity but lower specificity. Thus, these tools cannot fully replace functional characterization but can aid in reducing the number of variants that may require functional analysis.
BACKGROUND: Experts have proposed an 'EVEN FASTER' concept targeting age-groups maintaining circulation of human papillomavirus (HPV). We explored effects of the vaccination component of these proposals compared with cervical cancer (CC) screening-based interventions on age-standardized incidence rate (ASR) and CC elimination (<4 cases/100,000) timing in Norway.
METHODS: We used a model-based approach to evaluate HPV vaccination and CC screening scenarios compared with a status-quo scenario reflecting previous vaccination and screening. For cohorts ages 25-30 years, we examined 6 vaccination scenarios that incrementally increased vaccination coverage from current cohort-specific rates. Each vaccination scenario was coupled with three screening strategies that varied screening frequency. Additionally, we included 4 scenarios that alternatively increased screening adherence. Population- and cohort-level outcomes included ASR, lifetime risk of CC, and colposcopy referrals.
RESULTS: Several vaccination strategies coupled with de-intensified screening frequencies lowered ASR, but did not accelerate CC elimination. Alternative strategies that increased screening adherence could both accelerate elimination and improve ASR.
CONCLUSIONS: The vaccination component of an 'EVEN FASTER' campaign is unlikely to accelerate CC elimination in Norway but may reduce population-level ASR. Alternatively, targeting under- and never-screeners may both eliminate CC faster and lead to greater health benefits compared with vaccination-based interventions we considered.
PURPOSE: A health management device, a method thereof, and a graphic user interface are provided to supply a user interface for supplying health state information of a patient in response to input of a user through the user interface. CONSTITUTION: A screen(110) supplies information related to a health management service. An input unit(120) inputs a user. A storing unit(140) stores content corresponding to a digital image and a necessary program. A communication unit(150) receives the information about the health management service from a server(170). A processor(130) supplies the health management service through a screen.
Innate Defense Regulators (IDRs) interact with intracellular signaling events and modulate the innate defense response. Whereas much of the initial work with the IDRs focused on their role in fighting infection, recent results in animal models of chemotherapy- or radiation-induced mucositis and wound healing suggest that IDRs can be beneficial during the responses to a broader range of damage-inducing agents beyond pathogens. RIVPA (SEQ ID NO. 5), has demonstrated safety in humans and efficacy in animal models of fractionated radiation-induced and chemotherapy-induced oral mucositis, in models of chemotherapy induced damage to the gastro-intestinal tract and in models of local and systemic Gram-positive and Gram-negative infection in immunocompetent and immunocompromised hosts. Based on this information, we propose the use of RIVPA (SEQ ID NO. 5) and / or other IDRs (Table 1) as a novel treatment for Macrophage Activation Syndrome.
Ethambutol hydrochloride is an oral chemothera-peutic agent which is specifically effective against actively growing microorganisms of the genus Mycobacterium, including M. tuberculosis. It is a white, crystalline powder. Freely soluble in water; soluble in alcohol and in methanol; slightly soluble in ether and in chloroform. It has the chemical formula of: (+)-2,2’(Ethylenediimino)-di-1-butanol dihydrochloride. The structural formula is as follows:

C10H24N2O2·2HCl Molecular Weight: 277.23

Each tablet, for oral administration, contains 400 mg of ethambutol hydrochloride. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, compressible sugar, gelatin, hydroxypropyl methylcellulose, magnesium stearate, methylcellulose, polydextrose, polyethylene glycol, sodium lauryl sulfate, stearic acid, titanium dioxide, and triacetin.
Patients will receive inhaled N2O/O2 (70% N2O and 30% O2). A sterile bivalve speculum will be placed. Laminaria will be inserted. Inhaled N2O/O2 will be stopped after speculum removal.
PURPOSE: Intraoperative periprosthetic femoral fracture (IPFF) is a known iatrogenic complication during hemiarthroplasty (HA) which may lead to inferior outcomes. The risk factors for IPFF during HA in displaced femoral neck fractures (FNF) remains to be fully elucidated. This study aims to compare IPFF rates between compaction broaching and conventional broaching techniques for cementless HA in FNF.
METHODS: We retrospectively reviewed institutional surgical data of patients who underwent cementless HA for displaced FNF from January 2010 to January 2022. Patients were stratified into two groups based on the broaching system: conventional broaching and compaction broaching. The presence, location, and treatment of IPFF were assessed for both groups. Effect of IPFF on postoperative weight-bearing status, mortality readmission and revision rates were compared between groups.
RESULTS: A total of 1,586 patients included in the study. 1252 patients (78.9%) in the conventional broaching group and 334 patients (21.1%) in the compaction broaching group. A total of 104 IPFF were found (6.5%). As compared to conventional broaching, compaction broaching was associated with significant higher IPFF rates (12.9% vs. 4.9%, p < 0.001, OR 2.84, CI 1.88-4.30). The location of the IPFF was similar between groups (p = 0.366), as well as the intraoperative treatment (p = 0.103) and postoperative weight-bearing status (p = 0.640). Surgical time, mortality rates, readmission rates and revision rates were comparable between groups. In a multivariate regression analysis, compaction broaching (OR, 4.24; p < 0.001) was independently associated with IPFF.
CONCLUSIONS: This study reveals higher rates of IPFF associated with compaction broaching. Although this finding may have minimal clinical relevance, surgeons should consider these results when considering implant selection.
Penicillin is stabilized by admixture with 1 to 10 per cent by weight of an alkali metal phosphate or pyrophosphate or a mixture thereof, which in aqueous solution has a pH 7.0 to 9.0.  Preferred mixtures are (a) mono-and di-sodium phosphates containing between 10 and 50 per cent mono-sodium phosphate, and (b) normal and acid sodium pyrophosphate containing 5 to 40 per cent of the acid pyrophosphate. The penicillin is mixed with the dry salt in a sterile container and diluted with sterile water, glucose or saline solutions prior to use.ALSO:A method of producing stable penicillin preparations for injection in aqueous solution comprises introducing into a receptacle a solution of a buffer salt, evaporating such solution to dryness, dry-sterilizing the said receptacle and its contents and introducing solid penicillin into the sterile receptacle. When dissolved in sterile water, saline or glucose solution, the solution is stable within the normal limits of use, e.g. 4 days. To ensure complete sterility of bottles and the removal of pyrogens, the bottles must be subjected to dry heat at 250 DEG C for 1 hour.  Such sterilization precludes the use of buffers such as alkali metal citrates which decompose but may be carried out with alkali metal phosphates or pyrophosphates or mixtures thereof, which give aqueous solutions of pH 7.0 to 9.0.  Preferred mixtures are (a) mono- and di-sodium phosphates containing between 10 and 50 per cent of monosodium phosphate and (b) normal and acid sodium pyrophosphates containing between 5 and 40 per cent of the acid pyrophosphate.  The mixtures are used in the proportion of 1 to 10 per cent of the weight of the penicillin stabilized.
PURPOSE:To prepare the titled remedy free from particular side effects, usable also as a preventive, and enabling the radical remedy of allergic rhinitis and allergic asthma, by using gamma-linolenic acid which is an essential fatty acid as an active component. CONSTITUTION:A remedy for allergic rhinitis and allergic asthma can be prepared by using gamma-linolenic acid as an active component. Especially, evening primrose oil contains about 6% gamma-linolenic acid and about 72% linoleic acid in total fatty acid, and is preferable to be used as a composition containing gamma-linolenic acid. Dose: 5-30mg of gamma-linolenic acid daily, or 100-500mg of evening primrose oil daily. The remedy is effective at a low dose, and can be administered without feeing the ill odor of the evening primrose oil. The characteristic feature of the remedy is the preventive effect as well as the remedying effect.
The study was planned as a randomized controlled trial. The randomization process will be done as block randomization using the random interval command in Microsoft Excel. The participants to be included in the study will be selected from the clients receiving consultancy services at the Mehmet Gümüş (MG) Clinic Physiotherapy and Wellness Center. 50 individuals diagnosed with scoliosis who applied with a postural disorder complaint will be included in the study. The individuals will be randomly divided into 2 equal groups. The rehabilitation program of the 25 individuals in the first group will be planned as 3-dimensional corrective scoliosis exercises. The program of the 25 individuals in the second group will be applied as pilates scoliosis exercises. After the initial evaluations explained to the individuals included in the study are made, an exercise program of a total of 36 sessions, each lasting approximately 50 minutes, will be applied by experienced physiotherapists who have received 3-dimensional exercise method training and pilates training specific to scoliosis, 3 days a week for 12 weeks.